spacer
home > ebr > autumn 2003 > upping the anti - keeping ahead of antibiotic resistance
PUBLICATIONS
European Biopharmaceutical Review

Upping the Anti - Keeping Ahead of Antibiotic Resistance

The prevalence of antibacterial resistance seems to be rising, yet few new antibiotics have been approved in recent years. How dire is the situation and what is Enanta doing to address it?

Drug resistance is continually increasing and the supply of new antibiotics has slowed. Resistance to antibiotics varies by geographic region and there is no doubt that clinically important species of bacteria such as Streptococci, one of the major causes of respiratory tract infections, have developed resistance to more than one antibiotic. A recent study completed by the Centers for Disease Control in the US concluded that by next year 40 per cent of Streptococci will be resistant to both penicillins and macrolides.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Aimee Dingwell, News Editor at BioCentury Publications Inc, talks to Spiros Jamas, President and CEO of Enanta

Dr Spiros Jamas graduated from the University of Manchester Institute of Science and Technology, England, in 1981 with a BSc (Hons) in Chemical Engineering. He also holds a MSc in Food Science and Technology and a PhD in Biotechnology from the Massachusetts Institute of Technology.

In 1988, Dr Jamas founded and served as President, CEO and Director of Alpha-Beta Technology, a company that developed medical applications of carbohydrates. During his tenure at Alpha-Beta, he was instrumental in raising $200 million through venture capital, as well as public financings. Dr Jamas has also directed two INDs, five Phase I, three Phase II, and two Phase III clinical trials, while concurrently acquiring another privately held biotechnology company. Following this, he held the position of President and CEO of Repair Inc, a biopharmaceutical company that developed sustained-release angiogenesis therapies for the repair of diseased organs and tissues.

Dr Jamas has served as President and CEO of Enanta since the company's inception in 1999, providing scientific and business leadership.

spacer
Aimee Dingwell
spacer
spacer
spacer
Dr Spiros Jamas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharma pulls together biggest supply chain event in Europe for the life sciences sector

 
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
Industry Events

Pharma Supply and Logistics Innovation Program

6-7 June 2016, Hamburg, Germany

Pharma Supply and Logistics innovation program is a unique platform for 80+ Pharma and Biotech Companies with the collaborations of supply and logistics service providers.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement